News & Events

• August 3, 2015
  

  Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy

  August 3, 2015 Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy Tucson, Arizona – August 3, 2015: Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development, announced the formation of its tenth consortium: The Duchenne Regulatory Sciences Consortium (D-RSC). In...
• August 1, 2015
  

  Towards Host-Directed Therapies for Tuberculosis

  Zumla A, Maeurer M, Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JBW, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SHE, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS. Towards Host-Directed Therapies for Tuberculosis. Nature Reviews Drug Discovery. 2015 Aug;14(8):511–2.

• July 28, 2015
  

  Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm

  Gumbo T, Pasipanodya JG, Nuermberger E, Romero K, Hanna D. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2015 Jul 28;61 Suppl 1:S18–24.

• July 27, 2015
  

  FDA: Guidance for Industry Duchenne Muscular Dystrophy Developing Drugs for Treatment Over the Spectrum of Disease

• July 23, 2015
  

  CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia

  July 23, 2015 CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia Austin, TX – 23 July 2015 – The Clinical Data Interchange Standards Consortium (CDISC), the Critical Path Institute (C-Path), and TransCelerate BioPharma, Inc. are pleased to announce that data standards for clinical research in the areas of Schizophrenia, Hepatitis C...